OPEN END TURBO BULL - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 20:38:30 06/05/2024 BST | ||
| 19.65 EUR | +0.10% |
|
| Current month | +3.10% | ||
| 1 month | -2.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/05/24 | 19.65 | +0.10% | 0 |
| 03/05/24 | 19.63 | +0.46% | 0 |
| 02/05/24 | 19.54 | +2.52% | 0 |
| 30/04/24 | 19.06 | -0.26% | 0 |
| 29/04/24 | 19.11 | -1.29% | 0 |
Delayed Quote Börse Stuttgart
Last update May 06, 2024 at 08:38 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KF34ZN |
| ISIN | DE000KF34ZN2 |
| Date issued | 15/11/2021 |
| Strike | 192.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.4 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.11 € |
|---|---|
| Lowest since issue | 1.95 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
401.1
USD
Average target price
460.2
USD
Spread / Average Target
+14.75%
- Stock Market
- Certificates
- Certificat
